Gary Schwartz, MD

Gary K. Schwartz, MD, discusses the benefit of dose reducing ipilimumab plus nivolumab in metastatic sarcomas.

Gary K. Schwartz, MD, discusses future research efforts in the field of sarcoma.

Gary K. Schwartz, MD, discusses the results from the gastrointestinal stromal tumor cohort of the phase 2 Alliance A091401 trial.

Gary K. Schwartz, MD, discusses the updated design of the phase 2 Alliance A091401 trial for metastatic sarcomas.

Gary K. Schwartz, MD, discusses results of the Alliance A091401 trial (NCT02500797) in patients with metastatic sarcoma.

Gary Schwartz, MD, Baylor Scott & White Center for Thoracic Surgery, discusses the potential of single-agent durvalumab (Imfinzi) for the treatment of patients with stage III, locally advanced, unresectable non–small cell lung cancer (NSCLC).

Gary Schwartz, MD, a medical oncologist and chief of the Hematology and Oncology Division at Columbia University Medical Center, discusses a randomized phase III trial investigating eribulin (Halaven) versus dacarbazine in patients with leiomyosarcoma and adipocytic sarcomas.

The first and largest national clinical study to evaluate the safety and efficacy of an IGF-1R antibody and an mTOR inhibitor in combination therapy for a range of sarcomas has achieved its primary endpoint of improvement in progression-free survival at 12 weeks in patients with bone and soft-tissue sarcomas.